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Abstract
Approximately 200 million people are chronically infected with hepatitis C virus (HCV). Infection with HCV is curable by therapy, with
the current standard treatment based on the combination of pegylated interferon-a and ribavirin. Viral eradication is achieved in
approximately half of treated patients. In 2011 a new antiviral treatment based on a triple combination with a protease inhibitor will
become available. Virological tools are essential to diagnose HCV infection but they have found their principal application in guiding
treatment decisions and assessing the virological responses to therapy. These include the anti-HCV antibody assay, measurements of
HCV core antigen and HCV viral load and HCV genotyping. The HCV RNA can be ideally assayed by a real-time assay with a limit of
detection of 10–15 IU/mL. Monitoring of viral kinetics during the early phases of antiviral treatment is crucial in making treatment deci-
sions such as early stopping rules and also in optimizing the treatment duration. The HCV genotype should be assessed before the start
of treatment because it determines the treatment length and ribavirin dose and also offers prognostic information on treatment out-
comes as certain genotypes respond more favourably to treatment.
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Introduction
Approximately 200 million people are chronically infected
with hepatitis C virus (HCV) [1]. Each year, over 250 000
people die from HCV-related chronic liver disease, such as
end-stage cirrhosis and hepatocellular carcinoma. Infection
with HCV is curable by therapy, with the current standard
treatment based on the combination of pegylated interferon-
a (IFN-a) and ribavirin. Virus eradication, characterized by
the sustained virological response, i.e. an undetectable HCV
RNA 24 weeks after treatment completion, is achieved in
40–50% of patients infected with HCV genotype 1 and
approximately 80% of patients infected with genotypes 2 and
3 [2]. The outcome of therapy is inﬂuenced by several
parameters, including the treatment schedule, disease charac-
teristics, viral factors [3] and recently identiﬁed genetic fac-
tors that include single nucleotide polymorphisms located
upstream of the gene encoding IFN-k-3 (IL28B) [4–6]. In
2011, new antiviral treatments will be available for chronic
HCV genotype 1 infection. They will be based on the combi-
nation of pegylated IFN-a, ribavirin and a protease inhibitor,
either telaprevir or boceprevir. These therapies are associ-
ated with sustained virological response rates of about 70–
75% in treatment-naive patients and 50–60% in patients who
failed on previous therapy with pegylated IFN-a and ribavirin.
Virological tools are essential to diagnose HCV infection, but
they have found their principal application in guiding treat-
ment decisions and assessing the virological responses to
therapy.
Virological Markers and Tools
The virological diagnosis and monitoring of HCV infection is
based on the use of a variety of virological markers
(Table 1). Four HCV markers can be used in clinical practice,
including total anti-HCV antibodies, the HCV core antigen
level, the HCV RNA level and the HCV genotype.
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Detection of anti-HCV antibodies
The serological window, characterized by detectable HCV
RNA and core antigen in the absence of anti-HCV anti-
bodies, has been estimated to be approximately 60 days on
average [7]. Anti-HCV antibodies appear on average 2–8
weeks after the acute phase of infection and persist for life
in patients who develop chronic HCV infection (Fig. 1a).
The detection and eventual quantiﬁcation of speciﬁc anti-
bodies in body ﬂuids is based on the use of sandwich
enzyme immunoassays (EIAs). Recombinant antigens are
used to capture circulating antibodies onto the wells of mic-
rotitre plates, microbeads or speciﬁc holders adapted to
automated devices. The presence of antibodies is revealed
by anti-antibodies labelled with an enzyme that catalyses the
transformation of a substrate into a coloured compound.
The optical density (OD) ratio of the reaction (sample OD/
internal control OD) is proportional to the amount of anti-
bodies in the sample. The EIAs are cheap, easy to use, can be
fully automated and are easily adapted to large volume testing.
Other HCV antibody assays include anti-HCV IgM assays
and avidity tests. The signiﬁcance of the presence of anti-
HCV IgM during HCV infection is unclear. Anti-HCV IgMs
have been reported in 50–93% of patients with acute hepati-
tis C and 50–70% of patients with chronic hepatitis C [8–
10]. Therefore, anti-HCV IgM cannot be used as a reliable
marker of acute HCV infection and, so far, IgM assays have
not been used in clinical practice. However, increasing serial
measurements of anti-HCV IgM titres early after the onset
of the symptoms may help to identify patients with acute
hepatitis C [11]. Alternatively, an increase in the anti-HCV
IgG avidity index within a week after the onset of clinical
symptoms has also been reported to indicate acute HCV
infection [12]. Both parameters could be used together
before anti-HCV seroconversion occurs, or when no base-
line sample is available to conﬁrm the diagnosis of acute
infection [13].
HCV core antigen detection and quantiﬁcation
The HCV core antigen can be detected in peripheral blood
of infected individuals. Studies with different HCV core anti-
gen assays have shown that the HCV core antigen level is sig-
niﬁcantly related to the HCV RNA level, measured by means
of a molecular biology technique [14,15]. Quantiﬁcation of
HCV core antigen can therefore be considered an alternative
to HCV RNA level measurement because it is easy to per-
form in an immunoassay format, cheap, and less prone to
sample carryover contamination than molecular assays based
on target ampliﬁcation. Nevertheless, core antigen detection
is less sensitive than HCV RNA level detection and the core
antigen to HCV RNA ratio may vary slightly from one
infected patient to another. This may be because of the pres-
ence of HCV core antigen both in complete virions and in
RNA-free core protein structures in peripheral blood [14].
The analytical sensitivity of the recently developed Archi-
tect HCV assay (Abbott Laboratories, Abbott Park, IL) varies
according to the HCV genotype from 500 to 3000 interna-
tional units of HCV RNA per millilitre (IU/mL) [16]. The
HCV core antigen can be used in monitoring viral load in
patients treated for chronic hepatitis C, including the assess-
ment of the baseline replication level and assessment of the
virological responses to antiviral treatment [16,17]. Assays of
HCV core antigen could also be used as an alternative to
HCV RNA testing to screen blood, organ, tissue and cell
donors for acute infection [18].
TABLE 1. Virological markers for the diagnosis and man-
agement of hepatitis C virus (HCV) infection
Hepatitis C virus
Direct markers
HCV core antigen
HCV RNA
HCV genotype
HCV resistance proﬁlea
Indirect markers
Total anti-HCV antibodies
aNot routinely available.
(a) Anti-HCV antibodies
Anti-HCV antibodies
Symptoms +/–
Symptoms +/–
ALT
HCV RNA
Normal
Ti
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0 4 8 12 9616 20 48 144 192
Weeks
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36
(b)
ALT
HCV RNA
Normal
FIG. 1. Kinetics of virological markers during acute (a) and chronic
(b) hepatitis C virus (HCV) infection.
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Combo assays have been developed for the simultaneous
detection of anti-HCV antibodies and HCV core antigen.
The HCV combo assays detect acute HCV infection on aver-
age 20 days before third-generation antibody-only assays
[19] but they are less sensitive than third-generation anti-
HCV assays for antibody detection and detect HCV infection
later than HCV RNA assays. Combo assays could represent
an alternative to HCV RNA detection for diagnosis of acute
HCV infections or for blood screening when nucleic acid-
based technologies are not available.
HCV RNA level detection and quantiﬁcation
The presence of HCV RNA in peripheral blood is a reliable
marker of HCV replication. The HCV RNA can be detected
1–3 weeks after infection, approximately 1 month before the
appearance of total anti-HCV antibodies. The presence of
HCV RNA after 6 months denotes chronic HCV infection.
Levels of HCV RNA remain relatively stable over time in
chronically infected patients.
Viral genome detection and quantiﬁcation can be achieved
by using two categories of molecular biology-based tech-
niques, including target ampliﬁcation (such as PCR) and signal
ampliﬁcation (such as the branched DNA assay). Whatever
technique is used, HCV RNA IU/mL have become the pre-
ferred quantitative unit, and have now been implemented in
all commercial quantitative assays [20,21].
Real-time PCR techniques have a broad dynamic range of
quantiﬁcation, well suited to the clinical needs (upper range
of quantiﬁcation: 7–8 log10 IU/mL). In addition, real-time
PCR is more sensitive than classical PCR, with lower limits
of detection of the order of 10–15 IU/mL. These assays do
not yield false-positive results because of carryover contami-
nation, and they can be fully automated. As a result, real-
time PCR has become the technique of choice to detect and
quantify HCV RNA in clinical practice.
Two real-time PCR platforms are currently available for
the detection and quantiﬁcation of HCV RNA: the Cobas
Taqman platform, which can be used together with auto-
mated sample preparation with the Cobas AmpliPrep sys-
tem (CAP-CTM; Roche Molecular System, Pleasanton, CA),
and the Abbott platform (Abbott Diagnostic, Chicago, IL),
which uses the m2000RT ampliﬁcation platform together
with the m2000SP device for sample preparation. Other
assays, developed by Siemens Medical Solutions Diagnostics
(Tarrytown, NY) and Qiagen (GmbH, Hilden, Germany)
will be available soon. The intrinsic performances of avail-
able tests differ. Indeed, approximately 15% of HCV
genotype 2 and 30% of HCV genotype 4 clinical specimens
are substantially underestimated in the ﬁrst-generation
CAP-CTM assay, probably because of nucleotide polymor-
phisms at the hybridization sites for the PCR primers and
TaqMan probe in the 5¢ non-coding region of the genome,
whereas this problem has not been found with the Abbott
assay [22,23]. The failure to detect HCV RNA in a small
number of genotype 4 clinical specimens appeared to be
the result of the presence of two nucleotide polymor-
phisms at positions 145 and 165 [24,25]. A second-genera-
tion CAP-CTM assay will be available soon. HCV RNA
detection and quantiﬁcation are useful in clinical practice
to: (i) diagnose chronic HCV infection; (ii) identify patients
who need antiviral therapy; (iii) monitor the virological
responses to antiviral therapy; and (iv) document treat-
ment failure [21].
HCV genotype determination
Viral genome sequence analysis is generally based on direct
sequencing (so-called population sequencing) that provides
the full sequence of the analysed fragment, or reverse
hybridization that identiﬁes speciﬁc nucleotides or motifs at
given positions. Strains of HCV are classiﬁed into six geno-
types (1–6) and a large number of subtypes.
The reference method for viral genotype determination is
phylogenetic analysis of sequences generated after PCR
ampliﬁcation of a portion of the viral genome relative to ref-
erence sequences. Commercial assays have been developed.
The Trugene 5¢NC HCV Genotyping kit (Siemens Medical
Solutions Diagnostics) has been developed for HCV geno-
type determination by direct sequencing of a portion of the
5¢ non-coding region of the viral genome. Direct sequence
analysis identiﬁes viral variants that represent at least 20–
25% of the circulating viral populations.
Reverse hybridization of PCR amplicons to membrane-
bound probes is more sensitive than direct sequence analysis
to detect minor variants representing as few as 5% the
whole virus population [26]. Line probe assays (INNO-LiPA;
Innogenetics, Gent, Belgium) use a series of short immobi-
lized oligonucleotide probes to discriminate among different
PCR fragments. The most recent version of the line probe
assay for HCV genotype determination (VERSANT HCV
Genotype 2.0 Assay; Siemens Medical Solutions Diagnostics)
has consistently improved accuracy for HCV genotype 1 sub-
type and HCV genotype 6 determination compared with the
previous version of the assay [27–30].
Determination of HCV genotype is needed before the ini-
tiation of therapy with pegylated IFN-a and ribavirin because
it determines both the dose of ribavirin and the treatment
duration required [31]. In the future, genotype identiﬁcation
will also be used to identify genotype 1-infected patients
who should beneﬁt from the triple combination of pegylated
IFN-a, ribavirin and a protease inhibitor.
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HCV resistance testing
Several amino acid substitutions that confer resistance to
directly acting antiviral molecules, such as protease inhibi-
tors, have been identiﬁed. In case of a failure of the triple
combination of pegylated IFN-a, ribavirin and either telapre-
vir or boceprevir, HCV variants that are resistant to these
compounds are selected. Direct sequence analysis or reverse
hybridization methods can be used to identify amino acid
substitutions that confer resistance to antiviral drugs. Ultra-
deep sequencing methods, such as pyrosequencing, can
detect minor resistant populations down to <1%. At present,
no commercial resistance assay is available but ‘homebrew’
molecular methods have been developed in reference labora-
tories. If resistance testing is mandatory in clinical trials with
new directly acting antivirals, there will be no indication
before therapy and after treatment failure with the new tri-
ple combination of pegylated IFN-a, ribavirin and a protease
inhibitor.
Practical Use of Virological Tools in the
Management of Chronic Hepatitis C
Serological and molecular markers are used in clinical prac-
tice to diagnose hepatitis C infection, guide treatment deci-
sions and monitor the antiviral efﬁcacy of treatment.
Diagnosis of acute HCV infection
Patients suspected of acute hepatitis C infection should be
tested for both anti-HCV antibodies by EIA and HCV RNA
with a real-time PCR method with a lower limit of detection
of 10–15 IU/mL. An HCV core antigen test can be used
instead of the HCV RNA assay but diagnosis may be delayed
by a few days because these assays are less sensitive than
HCV RNA methods. Four marker proﬁles can be observed
according to the presence or absence of either marker. The
presence of HCV RNA in the absence of anti-HCV antibod-
ies is strongly indicative of acute HCV infection, which will
be conﬁrmed by seroconversion (i.e. the appearance of anti-
HCV antibodies) a few days to weeks later. Acutely infected
patients can also have both HCV RNA and anti-HCV anti-
bodies at the time of diagnosis. It is difﬁcult, in this case, to
distinguish acute hepatitis C from an acute exacerbation of
chronic hepatitis C or an acute hepatitis of another origin in
a patient with chronic hepatitis C.
Acute hepatitis C infection is unlikely if both anti-HCV
antibodies and HCV RNA or HCV core antigen are absent,
or if anti-HCV antibodies are present without HCV RNA or
HCV core antigen. The latter patients should be retested
after a period of 4 weeks at least because HCV RNA can be
temporarily undetectable because of transient, partial control
of viral replication before infection becomes chronic. Apart
from such cases, the presence of anti-HCV antibodies in the
absence of HCV RNA is generally observed in patients who
have recovered from a past HCV infection. Nevertheless,
this pattern cannot be differentiated from a false-positive EIA
result, the exact prevalence of which is unknown.
Diagnosis of chronic HCV infection
The persistence of HCV RNA for >6 months deﬁnes chronic
HCV infection (Fig. 1b). In patients with clinical or biological
signs of chronic liver disease, chronic hepatitis C infection is
diagnosed by the simultaneous presence of anti-HCV anti-
bodies and HCV RNA. Detectable HCV replication in the
absence of anti-HCV antibodies is occasionally observed with
third-generation anti-HCV EIA. It is almost exclusively
observed in profoundly immunodepressed patients, in
patients undergoing haemodialysis or in agammaglobulinaemic
subjects [32,33].
Treatment of HCV infection
The current standard treatment for chronic hepatitis C
infection is the combination of pegylated IFN-a2a or IFN-a2b
and ribavirin [34]. The future standard treatment of chronic
genotype 1 hepatitis C will be the triple combination of
pegylated IFN-a2a or IFN-a2b, ribavirin and a protease inhib-
itor, boceprevir or telaprevir. The efﬁcacy endpoint of
chronic hepatitis C treatment is the sustained virological
response, deﬁned by an undetectable HCV RNA in serum
with a sensitive assay (lower limit of detection of 10–15 IU/
mL) 24 weeks after the end of treatment.
Decision to treat and indication of treatment. The decision to
treat chronic hepatitis C depends on multiple parameters
including a precise assessment of the severity of liver disease,
the presence of absolute or relative contraindications to
therapy, and the patient’s willingness to be treated.
Determination of HCV genotype should be systematically
performed before treatment because it determines the dura-
tion of treatment, the dose of ribavirin and the virological
monitoring procedure (Fig. 2) [31]. Patients infected with
genotypes 2 and 3 require 24 weeks of treatment and a ﬁxed
low dose of ribavirin, i.e. 800 mg daily. However, in HCV
genotype 2/3-infected patients who have a rapid virological
response at week 4 (undetectable HCV RNA) and a low
HCV RNA level (<400 000–600 000 IU/mL) at baseline could
beneﬁt from a shorter treatment duration, i.e. 16 weeks [35].
In contrast, genotype 1-, 4-, 5- and 6-infected patients
require a high, bodyweight-based dose of ribavirin, i.e. 1000–
1400 mg daily, and treatment duration is tailored to the
CMI Chevaliez Virological tools to diagnose and monitor HCV infection 119
ª2010 The Author
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 116–121
on-treatment virological response. As soon as telaprevir and
boceprevir are approved, patients infected with HCV geno-
type 1, including treatment-naive patients and patients who
did not respond to a previous course of pegylated IFN-a and
ribavirin, will be treated with the triple combination of pegy-
lated IFN-a, ribavirin and telaprevir/boceprevir, in the
absence of contraindications.
Treatment monitoring. Monitoring of HCV RNA levels is rec-
ommended to tailor pegylated IFN-a and ribavirin treatment
to the actual virological response. A sensitive assay with a
broad range of quantiﬁcation, i.e. a real-time PCR assay,
should ideally be used. In HCV genotype 1-infected patients
(and probably also patients infected with genotypes 4, 5 and
6), the HCV RNA level should be measured before therapy,
and 4 and 12 weeks after its initiation (Fig. 2). Patients with
a rapid virological response at week 4 (undetectable HCV
RNA) and a low HCV RNA level (<400 000 IU/mL) at base-
line could beneﬁt from a shorter treatment duration, i.e.
24 weeks [36]. The lack of a 12-week virological response
(i.e. no change or an HCV RNA decrease of <2 log10 at
week 12) indicates that the patient has virtually no chance of
achieving a sustained virological response and should stop
treatment. In contrast, when a 2 log10 drop in HCV RNA
level has been observed at week 12, treatment must be con-
tinued either until week 48 if HCV RNA is undetectable at
week 12, or until week 72 if HCV RNA is still detectable at
week 12 [37–39]. The sustained virological response corre-
sponds to a cure of infection in >99% of cases [40].
The indication and rules for response-guided therapy with
triple combination treatments for HCV genotype 1 infection
will be established when ongoing Phase III trial data have
been published. With this treatment, the sustained virological
response will remain the endpoint of therapy. In patients
receiving the triple combination treatments who fail to have
HCV eradicated, the dominant virus at the time of the
breakthrough or relapse is most often resistant to the prote-
ase inhibitor. In the absence of alternative treatments, resis-
tance testing is not recommended in case of treatment
failure. This might change when more directly acting antiviral
drugs with different targets and mechanisms of action and
IFN-free regimens are available for the treatment of chronic
hepatitis C infection.
Monitoring of untreated chronic HCV infections
In patients with no indication for or with contraindications to
therapy, the HCV RNA level has no prognostic value. The
level of HCV replication does not correlate with the severity
of liver disease, or with the risk of liver disease progression
to cirrhosis or hepatocellular carcinoma. Repeated amino-
transferase level assessments are recommended. Assessment
of liver inﬂammation and ﬁbrosis by means of liver biopsy or
non-invasive serological or ultrasound-based testing is needed
in the case of persistent or intermittent elevations of amino-
transferase levels [34]. In patients with cirrhosis, assessment
for hepatocellular carcinoma by means of a-fetoprotein dose
and ultrasound examination is needed every 6 months.
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FIG. 2. Algorithms for the use of hepa-
titis C virus (HCV) virological tools in
the treatment of chronic hepatitis C,
according to the HCV genotype.
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